Fig. 4.
Adjusted HRs for switching across PASI and VAS joint pain levels at follow-upa. aModel also included age, sex, race, ethnicity, duration of PSO, biologic experience, baseline PASI/DLQI category, BMI, employment status, and number of concomitant diseases as well as biologic, non-biologic, topical, and phototherapy history (separately); bp < 0.001; cp = 0.276; dOf the four possible PASI/VAS combinations, the point shown by the orange triangle is a separate value comparing the worst combination (high PASI/high VAS) with the best (low PASI/low VAS) combination; those with high PASI/low VAS and low PASI/high VAS were not considered in this comparison. BMI body mass index, CI confidence interval, DLQI Dermatology Life Quality Index, HR hazard ratio, PASI Psoriasis Area Severity Index, PSO psoriasis, VAS visual analog scale